{"id":68874,"date":"2026-04-09T17:05:41","date_gmt":"2026-04-09T11:35:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68874"},"modified":"2026-04-09T17:05:42","modified_gmt":"2026-04-09T11:35:42","slug":"dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/","title":{"rendered":"Dr Reddy&#8217;s Laboratories Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"},"content":{"rendered":"<p>Dr Reddy&#8217;s Laboratories (NSE: DRREDDY) is trading at Rs 1,150 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Dr Reddy&#8217;s Laboratories share price target stands at Rs 1,350-1,550 \u2014 implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Current_Price_Overview\" title=\"Current Price Overview\">Current Price Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#About_Dr_Reddys_Laboratories\" title=\"About Dr Reddy&#8217;s Laboratories\">About Dr Reddy&#8217;s Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Catalysts_Driving_Dr_Reddys_Laboratories_Share_Price\" title=\"Key Catalysts Driving Dr Reddy&#8217;s Laboratories Share Price\">Key Catalysts Driving Dr Reddy&#8217;s Laboratories Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#1_gRevlimid_Lenalidomide_%E2%80%94_US_Opportunity\" title=\"1. gRevlimid (Lenalidomide) \u2014 US Opportunity\">1. gRevlimid (Lenalidomide) \u2014 US Opportunity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#2_Dr_Reddys_secured_a_settlement_to_launch_lenalidomide_generic_Revlimid_in_the_US_with_limited_competition_This_is_a_50_million_quarterly_revenue_opportunity_at_peak_and_is_the_largest_single_product_catalyst_for_DRL_in_FY26-FY27\" title=\"2. Dr Reddy&#8217;s secured a settlement to launch lenalidomide (generic Revlimid) in the US with limited competition. This is a $50 million+ quarterly revenue opportunity at peak and is the largest single product catalyst for DRL in FY26-FY27.\">2. Dr Reddy&#8217;s secured a settlement to launch lenalidomide (generic Revlimid) in the US with limited competition. This is a $50 million+ quarterly revenue opportunity at peak and is the largest single product catalyst for DRL in FY26-FY27.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#3_Biosimilars_Pipeline_%E2%80%94_Rituximab_Trastuzumab_Bevacizumab\" title=\"3. Biosimilars Pipeline \u2014 Rituximab, Trastuzumab, Bevacizumab\">3. Biosimilars Pipeline \u2014 Rituximab, Trastuzumab, Bevacizumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#4_Dr_Reddys_biosimilars_portfolio_%E2%80%94_rituximab_trastuzumab_bevacizumab_%E2%80%94_are_approved_and_selling_in_emerging_markets_US_biologics_market_entry_is_the_next_phase_starting_with_rituximab_in_FY27\" title=\"4. Dr Reddy&#8217;s biosimilars portfolio \u2014 rituximab, trastuzumab, bevacizumab \u2014 are approved and selling in emerging markets. US biologics market entry is the next phase, starting with rituximab in FY27.\">4. Dr Reddy&#8217;s biosimilars portfolio \u2014 rituximab, trastuzumab, bevacizumab \u2014 are approved and selling in emerging markets. US biologics market entry is the next phase, starting with rituximab in FY27.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#5_India_Branded_Formulations_Recovery\" title=\"5. India Branded Formulations Recovery\">5. India Branded Formulations Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#6_DRLs_India_formulations_business_grows_at_10-12_%E2%80%94_driven_by_Omez_pantoprazole_Stamlo_amlodipine_and_Cilacar_cilnidipine_Steady_branded_business_provides_earnings_floor\" title=\"6. DRL&#8217;s India formulations business grows at 10-12% \u2014 driven by Omez (pantoprazole), Stamlo (amlodipine), and Cilacar (cilnidipine). Steady branded business provides earnings floor.\">6. DRL&#8217;s India formulations business grows at 10-12% \u2014 driven by Omez (pantoprazole), Stamlo (amlodipine), and Cilacar (cilnidipine). Steady branded business provides earnings floor.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#7_European_Generics_%E2%80%94_Profitability_Recovery\" title=\"7. European Generics \u2014 Profitability Recovery\">7. European Generics \u2014 Profitability Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#8_Dr_Reddys_European_generic_portfolio_UK_Germany_France_is_recovering_profitability_after_years_of_price_erosion_Newer_product_launches_in_specialty_generics_are_improving_the_mix\" title=\"8. Dr Reddy&#8217;s European generic portfolio (UK, Germany, France) is recovering profitability after years of price erosion. Newer product launches in specialty generics are improving the mix.\">8. Dr Reddy&#8217;s European generic portfolio (UK, Germany, France) is recovering profitability after years of price erosion. Newer product launches in specialty generics are improving the mix.<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Risks_to_Dr_Reddys_Laboratories_Share_Price\" title=\"Key Risks to Dr Reddy&#8217;s Laboratories Share Price\">Key Risks to Dr Reddy&#8217;s Laboratories Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Technical_Analysis_and_Support_Levels\" title=\"Technical Analysis and Support Levels\">Technical Analysis and Support Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Latest_Quarterly_Financial_Performance\" title=\"Latest Quarterly Financial Performance\">Latest Quarterly Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Institutional_Positioning_%E2%80%94_FII_DII_Promoter\" title=\"Institutional Positioning \u2014 FII, DII, Promoter\">Institutional Positioning \u2014 FII, DII, Promoter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Dr_Reddys_Laboratories_Share_Price_Target_2026\" title=\"Dr Reddy&#8217;s Laboratories Share Price Target 2026\">Dr Reddy&#8217;s Laboratories Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#12-Month_Analyst_Target\" title=\"12-Month Analyst Target\">12-Month Analyst Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#FAQs\" title=\"FAQs\">FAQs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-laboratories-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Price_Overview\"><\/span><strong>Current Price Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>Current Market Price (CMP)<\/td><td>Rs 1,150<\/td><\/tr><tr><td>52-Week High<\/td><td>undefined<\/td><\/tr><tr><td>52-Week Low<\/td><td>undefined<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 96,000 Cr<\/td><\/tr><tr><td>P\/E Ratio<\/td><td>18x<\/td><\/tr><tr><td>12M Analyst Target<\/td><td>Rs 1,350-1,550<\/td><\/tr><tr><td>Bull Case<\/td><td>Rs 1,800<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 850<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Dr_Reddys_Laboratories\"><\/span><strong>About Dr Reddy&#8217;s Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p><p>Dr Reddy&#8217;s Laboratories (NSE: DRREDDY) is a leading listed company in the Pharma sector with a market capitalisation of Rs 96,000 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Catalysts_Driving_Dr_Reddys_Laboratories_Share_Price\"><\/span><strong>Key Catalysts Driving Dr Reddy&#8217;s Laboratories Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_gRevlimid_Lenalidomide_%E2%80%94_US_Opportunity\"><\/span><strong>1. gRevlimid (Lenalidomide) \u2014 US Opportunity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Dr_Reddys_secured_a_settlement_to_launch_lenalidomide_generic_Revlimid_in_the_US_with_limited_competition_This_is_a_50_million_quarterly_revenue_opportunity_at_peak_and_is_the_largest_single_product_catalyst_for_DRL_in_FY26-FY27\"><\/span><strong>2. Dr Reddy&#8217;s secured a settlement to launch lenalidomide (generic Revlimid) in the US with limited competition. This is a $50 million+ quarterly revenue opportunity at peak and is the largest single product catalyst for DRL in FY26-FY27.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Biosimilars_Pipeline_%E2%80%94_Rituximab_Trastuzumab_Bevacizumab\"><\/span><strong>3. Biosimilars Pipeline \u2014 Rituximab, Trastuzumab, Bevacizumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Dr_Reddys_biosimilars_portfolio_%E2%80%94_rituximab_trastuzumab_bevacizumab_%E2%80%94_are_approved_and_selling_in_emerging_markets_US_biologics_market_entry_is_the_next_phase_starting_with_rituximab_in_FY27\"><\/span><strong>4. Dr Reddy&#8217;s biosimilars portfolio \u2014 rituximab, trastuzumab, bevacizumab \u2014 are approved and selling in emerging markets. US biologics market entry is the next phase, starting with rituximab in FY27.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_India_Branded_Formulations_Recovery\"><\/span><strong>5. India Branded Formulations Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_DRLs_India_formulations_business_grows_at_10-12_%E2%80%94_driven_by_Omez_pantoprazole_Stamlo_amlodipine_and_Cilacar_cilnidipine_Steady_branded_business_provides_earnings_floor\"><\/span><strong>6. DRL&#8217;s India formulations business grows at 10-12% \u2014 driven by Omez (pantoprazole), Stamlo (amlodipine), and Cilacar (cilnidipine). Steady branded business provides earnings floor.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_European_Generics_%E2%80%94_Profitability_Recovery\"><\/span><strong>7. European Generics \u2014 Profitability Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Dr_Reddys_European_generic_portfolio_UK_Germany_France_is_recovering_profitability_after_years_of_price_erosion_Newer_product_launches_in_specialty_generics_are_improving_the_mix\"><\/span><strong>8. Dr Reddy&#8217;s European generic portfolio (UK, Germany, France) is recovering profitability after years of price erosion. Newer product launches in specialty generics are improving the mix.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_to_Dr_Reddys_Laboratories_Share_Price\"><\/span><strong>Key Risks to Dr Reddy&#8217;s Laboratories Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>US generics price erosion on base business:&nbsp;<\/strong><\/p><p><strong>gRevlimid volumes declining faster than expected:&nbsp;<\/strong><\/p><p><strong>FDA inspection risk at Duvvada and Srikakulam plants:&nbsp;<\/strong><\/p><p><strong>European pricing pressure continuing:&nbsp;<\/strong><\/p><p>The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_and_Support_Levels\"><\/span><strong>Technical Analysis and Support Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Dr Reddy&#8217;s Laboratories is trading at Rs 1,150 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,080-1,220. The 200-day moving average provides medium-term guidance for trend direction.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr Reddy&#8217;s Laboratories&#8217;s live price and get daily research insights.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Latest_Quarterly_Financial_Performance\"><\/span><strong>Latest Quarterly Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Key Metric<\/strong><\/td><td><strong>Latest Quarter<\/strong><\/td><td><strong>Year-Ago Quarter<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 8,359 Cr<\/td><td>Rs 7,507 Cr<\/td><td>+11.4%<\/td><\/tr><tr><td>Net Profit<\/td><td>Rs 1,413 Cr<\/td><td>Rs 1,279 Cr<\/td><td>+10.5%<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>24.6%<\/td><td>24.1%<\/td><td>+50 bps<\/td><\/tr><tr><td>US Revenue<\/td><td>Rs 3,680 Cr<\/td><td>Rs 3,280 Cr<\/td><td>+12.2%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track Dr Reddy&#8217;s Laboratories&#8217;s live financials on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Positioning_%E2%80%94_FII_DII_Promoter\"><\/span><strong>Institutional Positioning \u2014 FII, DII, Promoter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Promoter holds 26.7%. FII holding is 26.4% and DII holds 14.2%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dr_Reddys_Laboratories_Share_Price_Target_2026\"><\/span><strong>Dr Reddy&#8217;s Laboratories Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Subscribe to Univest Pro for Premium Stock Research and F&amp;O Setups<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Short-term support and trading range: Rs 1,080-1,220. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Target\"><\/span><strong>12-Month Analyst Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus for Dr Reddy&#8217;s Laboratories is Rs 1,350-1,550. The bear case \u2014 if FY27 guidance disappoints or macro headwinds intensify \u2014 is Rs 850. The bull case \u2014 on full earnings delivery and macro recovery \u2014 is Rs 1,800. These are analyst estimates based on publicly available data and may differ materially from actual price performance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For 2027-2028, analysts project Dr Reddy&#8217;s Laboratories toward the Rs 2,000-2,300 range \u2014 assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Dr Reddy&#8217;s Laboratories share price target for 2026 is Rs 1,350-1,550 based on analyst consensus. The bear case is Rs 850 and the bull case is Rs 1,800. At Rs 1,150, Dr Reddy&#8217;s Laboratories is trading at 18x P\/E with market cap of Rs 96,000 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit&nbsp;<\/p><p><a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a><\/p><p><strong>Disclaimer: <\/strong>This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Q1. What is Dr Reddy&#8217;s Laboratories share price target for 2026?<\/strong><\/p><p>The 12-month analyst consensus is Rs 1,350-1,550. Bull case: Rs 1,800. Bear case: Rs 850.<\/p><p><strong>Q2. Is Dr Reddy&#8217;s Laboratories a good buy at Rs 1,150?<\/strong><\/p><p>At 18x P\/E and Rs 1,150, Dr Reddy&#8217;s Laboratories offers potential recovery to Rs 1,350-1,550 over 12 months. Consult a SEBI-registered financial advisor before investing.<\/p><p><strong>Q3. What are the key risks for Dr Reddy&#8217;s Laboratories?<\/strong><\/p><p>Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.<\/p><p><strong>Q4. What is Dr Reddy&#8217;s Laboratories long-term share price target?<\/strong><\/p><p>Long-term target for FY28 is Rs 2,000-2,300, contingent on sustained earnings delivery and macro recovery.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/coal-india-share-price-target-2026\">Coal India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bharti-airtel-share-price-target\">Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/paytm-share-price-target\">Paytm Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Dr Reddy&#8217;s Laboratories (NSE: DRREDDY) is trading at Rs 1,150 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Dr Reddy&#8217;s Laboratories share price target stands at Rs 1,350-1,550 \u2014 implying meaningful upside from current levels. This article covers the current share price, key<\/p>\n","protected":false},"author":27,"featured_media":68876,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-68874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"_edit_lock":["1775734630:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_title":["Dr Reddy's Laboratories Share Price Target 2026: Analyst Forecast"],"rank_math_description":["Dr Reddy's Laboratories share price target 2026 \u2014 CMP Rs 1,150, consensus Rs 1,350-1,550. US Revlimid opportunity, biologics launches, India branded formulations. Bull case Rs 1,800.\n"],"rank_math_focus_keyword":["Dr Reddy's Laboratories"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["68876"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7686"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09170309\/Dr-Reddys-Labbs-Share-Price-Target.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68874"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68874\/revisions"}],"predecessor-version":[{"id":68882,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68874\/revisions\/68882"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68876"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}